American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) - PubMed (original) (raw)

Review

. 2010 Jul;134(7):e48-72.

doi: 10.5858/134.7.e48.

Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes, David G Hicks, Susan Lester, Richard Love, Pamela B Mangu, Lisa McShane, Keith Miller, C Kent Osborne, Soonmyung Paik, Jane Perlmutter, Anthony Rhodes, Hironobu Sasano, Jared N Schwartz, Fred C G Sweep, Sheila Taube, Emina Emilia Torlakovic, Paul Valenstein, Giuseppe Viale, Daniel Visscher, Thomas Wheeler, R Bruce Williams, James L Wittliff, Antonio C Wolff; American Society of Clinical Oncology; College of American Pathologists

Affiliations

• PMID: 20586616
• DOI: 10.5858/134.7.e48

Free article

Review

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)

M Elizabeth H Hammond et al. Arch Pathol Lab Med. 2010 Jul.

Free article

Abstract

Purpose: To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers.

Methods: The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER/PgR testing performance.

Results: Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in pre-analytic variables, thresholds for positivity, and interpretation criteria.

Recommendations: The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.

PubMed Disclaimer

Similar articles

• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
  Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. Hammond ME, et al. J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19. J Clin Oncol. 2010. PMID: 20404251 Free PMC article.
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
  Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. Hammond ME, et al. Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.5858/134.6.907. Arch Pathol Lab Med. 2010. PMID: 20524868 Free PMC article.
• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
  Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Allison KH, et al. J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13. J Clin Oncol. 2020. PMID: 31928404
• NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
  Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. Allred DC, et al. J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. doi: 10.6004/jnccn.2009.0079. J Natl Compr Canc Netw. 2009. PMID: 19755043 Review.
• Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
  Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology. Harris LN, et al. J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. J Clin Oncol. 2016. PMID: 26858339 Free PMC article. Review.

Cited by

• Financial Difficulty Over Time in Young Adults With Breast Cancer.
  Myers SP, Zheng Y, Dibble K, Mittendorf EA, King TA, Ruddy KJ, Peppercorn JM, Schapira L, Borges VF, Come SE, Rosenberg SM, Partridge AH. Myers SP, et al. JAMA Netw Open. 2024 Nov 4;7(11):e2446091. doi: 10.1001/jamanetworkopen.2024.46091. JAMA Netw Open. 2024. PMID: 39535790 Free PMC article.
• Quantitative Assessment of PALB2 and BRIP1 Genes Expression in the Breast Cancer Cell Line under the Influence of Tamoxifen.
  Kharrati-Koopaee H, Heydari ST, Dianatpour M, Bagheri Lankarani K. Kharrati-Koopaee H, et al. Galen Med J. 2023 Dec 26;12:1-8. doi: 10.31661/gmj.v12i0.2483. eCollection 2023. Galen Med J. 2023. PMID: 39430039 Free PMC article.
• Breast cancer molecular subtype classification according to immunohistochemistry markers and its association with pathological characteristics among women attending tertiary hospitals in Tanzania.
  Ismail A, Panjwani S, Ismail N, Ngimba C, Mosha I, Adebayo P, Mwanga A, Zehri AA, Njau A, Athar A. Ismail A, et al. Heliyon. 2024 Sep 26;10(19):e38493. doi: 10.1016/j.heliyon.2024.e38493. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39398050 Free PMC article.
• The novel selective inhibitors of cyclin-dependent kinase 4/6: in vitro and in silico study.
  Susanti NMP, Kurniawan F, Damayanti S, Kartasasmita RE, Tjahjono DH. Susanti NMP, et al. Sci Rep. 2024 Oct 9;14(1):23505. doi: 10.1038/s41598-024-71865-7. Sci Rep. 2024. PMID: 39379427 Free PMC article.
• EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.
  Wu F, Li N, Wu X, Chen M, Huang W, Chen X, Hong Y, Wang L, Chen K, Lin L, You M, Liu J. Wu F, et al. BMC Cancer. 2024 Sep 19;24(1):1166. doi: 10.1186/s12885-024-12950-y. BMC Cancer. 2024. PMID: 39300407 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program